NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Newsletters
Advertisement
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
HONcode
Security by Verisign

Thyroid Disease


Return to Library

Free Thyroid Disease Articles


Investigators at Mayo Clinic have published new data on alcoholism immunology



2009 JUL 20 - (NewsRx.com) -- A new study, 'Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease,' is now available. "Primary biliary cirrhosis (PBC) is frequently associated with autoimmune diseases, including thyroid disease, although it is uncertain that this association is higher than in other liver diseases. We compared the prevalence and incidence of thyroid dysfunction (TD) in a series of patients with PBC (n=67) with patients with primary sclerosing cholangitis (PSC) (n=79) and non-alcoholic fatty liver disease (NAFLD) (n=97) seen in a tertiary referral centre who had previously participated in clinical trials," researchers in the United States report.

"At initial evaluation, prevalence of TD in PBC was 13% compared with 11% in PSC (p=0.71) and 25% in NAFLD (p=0.08). Incidence of TD was 2.9 patients per 100 person-years in PBC compared with 2.1 patients per 100 person-years in PSC (p=0.57) and 1.8 patients per 100 person-years in non-alcoholic liver disease (p=0.45). Older age, female gender, biochemical abnormalities and concurrent autoimmune disorders were not predictive of the development of TD. TD was unexpectedly as common in patients with PBC as in patients with PSC and NAFLD, yet significantly more common than expected in the general population," wrote M.G. Silveira and colleagues, Mayo Clinic.

The researchers concluded: "Further investigation of thyroid disease in PSC and NAFLD is warranted."

Silveira and colleagues published their study in Liver International (Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver International, 2009;29(7):1094-100).

For additional information, contact M.G. Silveira, Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, MN 55905 USA..

Publisher contact information for the journal Liver International is: Blackwell Publishing Inc., 350 Main St., Malden, MA 02148, USA.

Keywords: United States, Rochester, Alcoholism Immunology, Addiction Medicine, Alcoholism, Autoimmune Diseases, Autoimmune Disorder, Biliary Cirrhosis, Cirrhosis, Clinical Trial Research, Fatty Liver, Fibrosis, Gastroenterology, Hepatology, Immunology, Liver Disease, Mental Health, Primary Sclerosing Cholangitis, Sclerosing Cholangitis, Thyroid Disease.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login